Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial
Jaclyn Smith, Michael Kitt, Alyn Morice, Surinder Birring, Lorcan McGarvey, Mandel Sher, Anthony Ford
European Respiratory Journal 2017 50: OA2932; DOI: 10.1183/1393003.congress-2017.OA2932
Jaclyn Smith
1University of Manchester, Manchester, United Kingdom
Michael Kitt
2Merck & Co., Inc., Kenilworth, United States of America
Alyn Morice
3Hull York Medical School, Cottingham, United States of America
Surinder Birring
2Merck & Co., Inc., Kenilworth, United States of America
Lorcan McGarvey
4Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom
Mandel Sher
5Center for Cough, Largo, United States of America
Anthony Ford
2Merck & Co., Inc., Kenilworth, United States of America
Vol 50 Issue suppl 61
Table of Contents
Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial
Jaclyn Smith, Michael Kitt, Alyn Morice, Surinder Birring, Lorcan McGarvey, Mandel Sher, Anthony Ford
European Respiratory Journal Sep 2017, 50 (suppl 61) OA2932; DOI: 10.1183/1393003.congress-2017.OA2932
Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial
Jaclyn Smith, Michael Kitt, Alyn Morice, Surinder Birring, Lorcan McGarvey, Mandel Sher, Anthony Ford
European Respiratory Journal Sep 2017, 50 (suppl 61) OA2932; DOI: 10.1183/1393003.congress-2017.OA2932